Cassava Sciences, Inc. (SAVA)

Cassava Sciences, Inc., a clinical-stage drug development company, develops drugs for nervous system disorders. The company's lead therapeutic product candidate PTI-125, a small molecule drug that is in Phase II clinical trial for the treatment of Alzheimer's disease. It is also developing PTI-125Dx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was founded in 1998 and is based in Austin, Texas.

Current Quote*
Last: $7.994
Change: 0.184
Book: $7.789
Volume: 608,186

As Of: 01/22 13:00 ET
*Quotes delayed by 20min.

Graphs for SAVA


3 Month Graph


6 Month Graph


1 Year Graph